Specify Company / Ticker to Get the Summary
Dividend History BMEA
Dividend Analytics BMEA
Max Ratio
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Biomea Fusion Inc
BMEABiomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It's lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in San Carlos, California. Address: 1599 Industrial Road, San Carlos, CA, United States, 94070
Analytics
WallStreet Target Price
18.25 USDP/E Ratio
–Dividend Yield
–Financials BMEA
Results | 2019 | Dynamics |